BD-PT2073

Group VI iPLA2 Rabbit Polyclonal Antibody

PLA2G6; PLPLA9; 85/88 kDa calcium-independent phospholipase A2; CaI-PLA2; Group VI phospholipase A2; GVI PLA2; Intracellular membrane-associated calcium-independent phospholipase A2 beta; iPLA2-beta; Patatin-like phospholipase domain-contai

常规抗体

PLA2G6

85/88 kDa calcium-independent phospholipase A2

WB

Human,Mouse,Rat

1 mg/ml

Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% New type preservative N.

8398

http://www.ncbi.nlm.nih.gov/sites/entrez?db=gene&term=8398

O60733

http://www.uniprot.org/uniprotkb/O60733/entry

53357

http://www.ncbi.nlm.nih.gov/sites/entrez?db=gene&term=53357

P97819

http://www.uniprot.org/uniprot/P97819

360426

http://www.ncbi.nlm.nih.gov/sites/entrez?db=gene&term=360426

P97570

http://www.uniprot.org/uniprot/P97570

Synthesized peptide derived from the Internal region of human Group VI iPLA2.

Group VI iPLA2 Polyclonal Antibody detects endogenous levels of Group VI iPLA2 protein.

WB 1:500-2000

90kD

-20°C/1 year

Polyclonal, Rabbit,IgG

The protein encoded by this gene is an A2 phospholipase, a class of enzyme that catalyzes the release of fatty acids from phospholipids. The encoded protein may play a role in phospholipid remodelling, arachidonic acid release, leukotriene and prostaglandin synthesis, fas-mediated apoptosis, and transmembrane ion flux in glucose-stimulated B-cells. Several transcript variants encoding multiple isoforms have been described, but the full-length nature of only three of them have been determined to date. [provided by RefSeq, Dec 2010],

Four different transcripts were found to be expressed in a distinct tissue distribution.

Cytoplasm . Cell membrane . Mitochondrion . Cell projection, pseudopodium . Recruited to the membrane-enriched pseudopods upon MCP1/CCL2 stimulation in monocytes. .

Glycerophospholipid metabolism;Ether lipid metabolism;Arachidonic acid metabolism;Linoleic acid metabolism;alpha-Linolenic acid metabolism;MAPK_ERK_Growth;MAPK_G_Protein;Vascular smooth muscle contraction;VEGF;Fc epsilon RI;Fc gamma R-mediated phagocytosi

catalytic activity:Phosphatidylcholine + H(2)O = 1-acylglycerophosphocholine + a carboxylate.,disease:Defects in PLA2G6 are a cause of neurodegeneration with brain iron accumulation (NBIA) [MIM:610217]. NBIA comprises a clinically and genetically heterogeneous group of disorders with high basal ganglia iron.,disease:Defects in PLA2G6 are the cause of infantile neuroaxonal dystrophy 1 (INAD1) [MIM:256600]; also known as Seitelberger disease. Infantile neuroaxonal dystrophy (INAD) is a neurodegenerative disease characterized by pathologic axonal swelling and spheroid bodies in the central nervous system. Onset is within the first 2 years of life with death by age 10 years.,disease:Defects in PLA2G6 are the cause of Karak syndrome [MIM:608395]. Karak syndrome is a neurologic disease characterized by early-onset progressive cerebellar ataxia, dystonia, spasticity, intellectual and features compatible with iron deposition in the putamen and substantia nigra.,function:Catalyzes the release of fatty acids from phospholipids. It has been implicated in normal phospholipid remodeling, nitric oxide-induced or vasopressin-induced arachidonic acid release and in leukotriene and prostaglandin production. May participate in fas mediated apoptosis and in regulating transmembrane ion flux in glucose-stimulated B-cells.,function:Isoform ankyrin-iPLA2-1 and isoform ankyrin-iPLA2-2, which lack the catalytic domain, are probably involved in the negative regulation of iPLA2 activity.,similarity:Contains 7 ANK repeats.,subunit:Forms large oligomeric 270-350 kDa structures.,tissue specificity:Four different transcripts were found to be expressed in a distinct tissue distribution.,

现货

The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.